グレンマーク ファーマシューティカルズ， エセ．アー．;GLENMARK PHARMACEUTICALS SA
发明人:
HARALD MOTTL,モットル， ハラルド,モットル, ハラルド
申请号：
JP2015062978
公开号：
JP2015145397A
申请日:
2015.03.25
申请国别(地区):
JP
年份:
2015
代理人:
摘要：
PROBLEM TO BE SOLVED: To provide a method for treating cancer.SOLUTION: The invention provides a method for treating cancer by administering anti-&alpha；2&bgr；1 integrin antibody, where the cancer is selected from squamous cell cancer, lung cancer, peritoneal cancer, hepatocellular cancer, gastric cancer including digestive cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrium carcinoma or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B cell lymphoma including low grade/follicular non-Hodgkin lymphoma (NHL)； small lymphocytic (SL) NHL； NHL； intermediate grade diffuse NHL and Waldenstrom's Macroglobulinemia. Humanized anti-&alpha；2 integrin antibody comprising a heavy chain variable region being HCRD2, HCRD1 or HCDR3, and/or a light chain variable region being LCDR1, LCDR2 or LCDR3.【課題】癌を処置するための方法。【解決手段】抗α２β１インテグリン抗体を投与する、扁平上皮細胞癌、肺癌、腹膜の癌、肝細胞癌、胃癌（消化器癌を含む）、膵癌、神経膠芽腫、子宮頸癌、卵巣癌、肝臓癌、膀胱癌、ヘパトーム、乳癌、結腸癌、結腸直腸癌、子宮内膜癌腫又は子宮癌腫、唾液腺癌腫、腎臓癌又は腎癌、肝臓癌、前立腺癌、外陰部の癌、甲状腺癌、肝癌腫及び様々なタイプの頭頸部癌、並びにＢ細胞リンパ腫（非ホジキンリンパ腫（ＮＨＬ）；小リンパ球性（ＳＬ）ＮＨＬ；ＮＨＬ；中悪性度びまん性ＮＨＬ；及びワルデンシュトレームマクログロブリン血症を含む）から選択される癌を処置する方法の提供。ＨＣＲＤ２、ＨＣＲＤ１、及びＨＣＤＲ３等の重鎖可変可能領域、及び／又は、ＬＣＤＲ１、ＬＣＤＲ２、ＬＣＤＲ３の軽鎖可変領域を含むヒト化抗α２インテグリングリン抗体。【選択図】なし
